EXHIBIT 10.14
AMENDMENT NO. 1 TO
LICENSE AGREEMENT
Pursuant to Section 15.2 of the License Agreement dated as of April 15, 1999
between Pharmaceutical Applications Associates LLC, C. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.,
C.G.P., ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇.▇▇. and PRAECIS PHARMACEUTICALS INCORPORATED (the
"Agreement"), the parties hereto, intending to be legally bound, hereby agree as
follows:
Section 4.6 of the Agreement is hereby amended in its entirety to read as
follows:
4.6 In the event that Licensee elects, in its sole
discretion, to initiate a Phase III study of the Licensed Product, Licensee
shall pay to PAA the sum of fifty thousand dollars ($50,000) within sixty
(60) days of the treatment of the first patient.
Capitalized terms used herein and not otherwise defined shall have the meanings
ascribed to such terms in the Agreement.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the parties have duly executed this
Amendment No. 1 to the Agreement as of this 25th day of August, 2000.
PRAECIS PHARMACEUTICALS INCORPORATED
/s/ ▇▇▇▇ ▇. Silver
------------------------------------------
▇▇▇▇ ▇. Silver
Vice President of Corporate Development
PHARMACEUTICAL APPLICATIONS ASSOCIATES LLC
By /s/ C. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D., C.G.P.
------------------------------------------
Name: C. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D., C.G.P.
Title: President